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1Dear Editor,
This is an author response to the letter by doctors Nicholas Doher and 
Harsh V Gupta.
Despite the narrow indication for the dopamine transporter (DAT) scan 
to distinguish essential tremor from Parkinsonian syndromes, as approved 
by the Food and Drug Administration (FDA), (Available from: http://www.
accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.
pdf) DAT imaging is utilised for various other clinical symptoms in patients 
with parkinsonism: (1) to differentiate Parkinson’s disease (PD) from atypical 
parkinsonism (dementia with Lewy bodies (DLB), multiple system atrophy 
(MSA), corticobasal degeneration (CBD), etc.), vascular parkinsonism or 
psychogenic parkinsonism by revealing different patterns of  decreased DAT 
uptake or the lack thereof,1,2 (2) as a marker, in PD prognostics, in that it 
reflects the severity of  the disease,3,4 (3) as a predictor for levodopa-induced 
dyskinesias,5 (4) for differential diagnosis of  PD from dopa-responsive dysto-
nia6,7 or drug-induced parkinsonism8 and (5) to differentiate dystonic or psy-
chogenic tremors from tremors due to PD.9 Additionally, false negativity or 
positivity, along with the advent of  the novel terminology, scan without evi-
dence of  dopaminergic deficit (SWEDD) syndrome, is another compelling 
issue. DAT scan is the only non-invasive modality developed to assess func-
tional integrity of  the dopaminergic system currently used in clinical prac-
tice, and could give valuable clinical information for selected patients. We 
do think that, the approved indication of  the DAT scan will be broadened 
to meet its versatile diagnostic potential.
Our patient exhibited definite parkinsonism after increasing the dose of  
the typical antipsychotic medication (haloperidol); it was therefore important 
to ensure whether parkinsonism resulted solely from haloperidol or if  there 
actually was subclinical parkinsonism present and haloperidol triggered its 
manifestation. If  the latter case was true, parkinsonism had to be considered 
as a symptom accompanying chorea and dystonia in the natural course of  
the disease, broadening the diagnostic spectrum. Although decreased DAT 
uptake was observed in our patient, the ‘pattern’ of  decreased uptake was 
different from classic Parkinsonian syndromes. Moreover, we already 
obtained the data from magnetic resonance imaging (MRI) of  the brain  in 
Columbia University Libraries
Freely available online
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
Citation: Ha J, Na BS, Ahn JH, Kim M, Kim JW, Lee JH, et al. Author response to letter to the editor. Tremor Other Hyperkinet Mov. 2019: 9. doi: 10.7916/tohm.v0.746
*To whom correspondence should be addressed. E-mail: genian@skku.edu
†These two authors contributed equally to this work.
Editor: Elan D. Louis, Yale University, USA
Received: November 4, 2019; Accepted: November 4, 2019; Published: December 2, 2019
Copyright: © 2019 Ha et al. This is an open-access article distributed under the terms of  the Creative Commons Attribution–Non-commercial–No Derivatives 
License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made 
of  the work; and that the work is not altered or transformed.
Funding: None.
Financial Disclosures: None.
Conflict of Interest: The authors report no conflict of  interest.
Ethics Statement: Not applicable for this category of  article.
In Response To:
Doher N, Gupta HV. Reply to: Paraneoplastic Chorea Managed with Intravenous Amantadine. Tremor Other Hyperkinet Mov. 2019; 9. doi: 10.7916/tohm.v0.743 
Original Article:
Ha J, Na BS, Ahn JH, Kim M, Kim JW, Lee JH, et al. Anti-CV2/CRMP5 paraneoplastic chorea effectively managed with intravenous amantadine. Tremor Other 
Hyperkinet Mov. 2019: 9. doi: 10.7916/tohm.v0.701
Letters
Author Response to Letter to the Editor
Jongmok Ha1,2†, Boo Suk Na3†, Jong Hyeon Ahn1,2, Minkyeong Kim1,2, Jae Woo Kim4, Jae Hyeok Lee5, Jin Whan Cho1,2,  
Ji Sun Kim1,2 & Jinyoung Youn1,2*
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, 2Neuroscience Center, Samsung Medical 
Center, Seoul, KR, 3Department of Neurology, Dongshin Hospital, Seoul, KR, 4Department of Neurology, Dong-A University College of Medicine, Busan, KR, 
5Department of Neurology, Pusan National University Yangsan Hospital, Yangsan, KR
Ha J, Na BS, Ahn JH, et al. Letter to the Editor
Columbia University Libraries
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org 2
advance to co-localise and compare with the DAT scan data; therefore, we 
were not threatened by the caveats of  false-positivity.
In conclusion, we believe that in atypical, complex cases that warrant 
prompt diagnosis and treatment, it does not harm the patient to undergo 
relevant tests, if  not disorienting. Our patient was in desperate need of  
a concrete diagnosis in order to terminate his diagnostic odyssey and the 
DAT scan played a crucial role in our workup.
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